Literature DB >> 25309092

Problem of living liver donation in the absence of deceased liver transplantation program: Mansoura experience.

Mohamed Abdel Wahab1, Hosam Hamed1, Tarek Salah1, Waleed Elsarraf1, Mohamed Elshobary1, Ahmed Mohamed Sultan1, Ahmed Shehta1, Omar Fathy1, Helmy Ezzat1, Amr Yassen1, Mohamed Elmorshedi1, Mohamed Elsaadany1, Usama Shiha1.   

Abstract

We report our experience with potential donors for living donor liver transplantation (LDLT), which is the first report from an area where there is no legalized deceased donation program. This is a single center retrospective analysis of potential living donors (n = 1004) between May 2004 and December 2012. This report focuses on the analysis of causes, duration, cost, and various implications of donor exclusion (n = 792). Most of the transplant candidates (82.3%) had an experience with more than one excluded donor (median = 3). Some recipients travelled abroad for a deceased donor transplant (n = 12) and some died before finding a suitable donor (n = 14). The evaluation of an excluded donor is a time-consuming process (median = 3 d, range 1 d to 47 d). It is also a costly process with a median cost of approximately 70 USD (range 35 USD to 885 USD). From these results, living donor exclusion has negative implications on the patients and transplant program with ethical dilemmas and an economic impact. Many strategies are adopted by other centers to expand the donor pool; however, they are not all applicable in our locality. We conclude that an active legalized deceased donor transplantation program is necessary to overcome the shortage of available liver grafts in Egypt.

Entities:  

Keywords:  Deceased donor; Excluded donors; Liver disease; Liver transplantation; Living donor

Mesh:

Year:  2014        PMID: 25309092      PMCID: PMC4188913          DOI: 10.3748/wjg.v20.i37.13607

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  24 in total

1.  Live liver donation: a prospective analysis of exclusion criteria for healthy and potential donors.

Authors:  E Moreno Gonzalez; J C Meneu Diaz; I Garcia Garcia; C Loinaz Segurola; C Jimenez; R Gomez; M Abradelo; A Moreno Elola; S Jimenez; E Ferrero; J Calvo; A Manrique; M L Herrero
Journal:  Transplant Proc       Date:  2003-08       Impact factor: 1.066

2.  Experience after the evaluation of 700 potential donors for living donor liver transplantation in a single center.

Authors:  Camino Valentín-Gamazo; Massimo Malagó; Marc Karliova; Juergen T Lutz; Andrea Frilling; Silvio Nadalin; Giuliano Testa; Stefan G Ruehm; Yesim Erim; Andreas Paul; Hauke Lang; Guido Gerken; Christoph E Broelsch
Journal:  Liver Transpl       Date:  2004-09       Impact factor: 5.799

3.  Lessons learned from 1,000 living donor liver transplantations in a single center: how to make living donations safe.

Authors:  Shin Hwang; Sung-Gyu Lee; Young-Joo Lee; Kyu-Bo Sung; Kwang-Min Park; Ki-Hun Kim; Chul-Soo Ahn; Deok-Bog Moon; Gyu-Sam Hwang; Kyung-Mo Kim; Tae-Yong Ha; Dong-Sik Kim; Jae-Pil Jung; Gi-Won Song
Journal:  Liver Transpl       Date:  2006-06       Impact factor: 5.799

4.  Long-term follow-up after liver transplantation in Egyptians transplanted abroad.

Authors:  Hatem Khalaf; Sherif Farag; Ehab El-Hussainy
Journal:  Saudi Med J       Date:  2004-12       Impact factor: 1.484

Review 5.  Liver transplant from Anti-HBc-positive, HBsAg-negative donor into HBsAg-negative recipient: is it safe? A systematic review of the literature.

Authors:  Vivian Iida Avelino-Silva; Luiz Augusto Carneiro D'Albuquerque; Patrícia Rodrigues Bonazzi; Alice Tung Wan Song; João Luiz Miraglia; Alan De Brito Neves; Edson Abdala
Journal:  Clin Transplant       Date:  2010 Nov-Dec       Impact factor: 2.863

6.  Splenectomy does not offer immunological benefits in ABO-incompatible liver transplantation with a preoperative rituximab.

Authors:  Vikram Raut; Akira Mori; Toshimi Kaido; Yasuhiro Ogura; Iida Taku; Kazuyuki Nagai; Naoya Sasaki; Kosuke Endo; Toshiyuki Hata; Shintaro Yagi; Hiroto Egawa; Shinji Uemoto
Journal:  Transplantation       Date:  2012-01-15       Impact factor: 4.939

7.  Present status of ABO-incompatible living donor liver transplantation in Japan.

Authors:  Hiroto Egawa; Satoshi Teramukai; Hironori Haga; Minoru Tanabe; Masanori Fukushima; Motohide Shimazu
Journal:  Hepatology       Date:  2008-01       Impact factor: 17.425

Review 8.  Use of hepatitis B core antibody-positive donors for liver transplantation.

Authors:  Santiago J Muñoz
Journal:  Liver Transpl       Date:  2002-10       Impact factor: 5.799

9.  Donor evaluation for living-donor liver transplantation.

Authors:  M Haberal; R Emiroglu; S Boyactoğlu; B Demirhan
Journal:  Transplant Proc       Date:  2002-09       Impact factor: 1.066

10.  ABO-incompatible liver transplantation for critically ill adult patients.

Authors:  Christian Toso; Mohammed Al-Qahtani; Faisal A Alsaif; David L Bigam; Glenda A Meeberg; A M James Shapiro; Vincent G Bain; Norman M Kneteman
Journal:  Transpl Int       Date:  2007-05-22       Impact factor: 3.782

View more
  3 in total

1.  Spray Diathermy Versus Harmonic Scalpel Technique for Hepatic Parenchymal Transection of Living Donor.

Authors:  Mohamed El Shobary; Tarek Salah; Ayman El Nakeeb; Ahmad M Sultan; Ahmed Elghawalby; Omar Fathy; Mohamed Abdel Wahab; Amro Yassen; Mohamed Elmorshedy; Wagdi F Elkashef; Usama Shiha; Mohamed Elsadany
Journal:  J Gastrointest Surg       Date:  2016-10-31       Impact factor: 3.452

Review 2.  Living donor liver transplantation in Egypt.

Authors:  Khaled E Amer; Ibrahim Marwan
Journal:  Hepatobiliary Surg Nutr       Date:  2016-04       Impact factor: 7.293

3.  The impact of metabolic syndrome and prevalent liver disease on living donor liver transplantation: a pressing need to expand the pool.

Authors:  Waleed Al-Hamoudi; Faisal Abaalkhail; Abdurahman Bendahmash; Naglaa Allam; Bassem Hegab; Yasser Elsheikh; Hamad Al-bahili; Nasser Almasri; Mohammed Al-sofayan; Saleh Alabbad; Mohammed Al-Sebayel; Dieter Broering; Hussien Elsiesy
Journal:  Hepatol Int       Date:  2015-09-04       Impact factor: 6.047

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.